Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total value of $608,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,302,987 shares of the company’s stock, valued at $52,875,212.46. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 8th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.85, for a total value of $732,750.00.
• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00.

Apogee Therapeutics Price Performance

Shares of APGE traded down $1.92 during mid-day trading on Friday, reaching $39.72. The company’s stock had a trading volume of 385,519 shares, compared to its average volume of 506,977. Apogee Therapeutics, Inc. has a 12-month low of $33.14 and a 12-month high of $72.29. The stock has a market cap of $1.79 billion, a PE ratio of -16.41 and a beta of 2.18. The company’s 50 day moving average is $44.25 and its 200 day moving average is $48.53.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.13). As a group, sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on APGE shares. Wedbush lifted their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, December 12th. Canaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Finally, Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $89.71.

Hedge Funds Weigh In On Apogee Therapeutics

Several hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at about $71,000. Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after buying an additional 285 shares during the period. Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics in the fourth quarter valued at approximately $216,000. Wexford Capital LP purchased a new position in shares of Apogee Therapeutics during the third quarter worth approximately $230,000. Finally, Arizona State Retirement System increased its holdings in shares of Apogee Therapeutics by 17.3% in the 4th quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after acquiring an additional 960 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.